KENLIVABY

Serial Number 90827345
606

Registration Progress

Application Filed
Jul 14, 2021
Under Examination
Sep 13, 2022
Approved for Publication
Jul 19, 2022
Published for Opposition
Jul 19, 2022
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: KENLIVABY
Previous Owner: Idorsia Pharmaceuticals Ltd
Classes: 005

Trademark Image

KENLIVABY

Basic Information

Serial Number
90827345
Filing Date
July 14, 2021
Published for Opposition
July 19, 2022
Abandonment Date
October 10, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Oct 10, 2025
Classes
005

Rights Holder

Idorsia Pharmaceuticals Ltd

09
Address
Hegenheimermattweg 91
Allschwil 4123
CH

Ownership History

Idorsia Pharmaceuticals Ltd

Original Applicant
09
Allschwil CH

Idorsia Pharmaceuticals Ltd

Owner at Publication
09
Allschwil CH

Legal Representation

Attorney
Gail I. Nevius Abbas

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

33 events
Date Code Type Description Documents
Oct 10, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Oct 10, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Sep 3, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 3, 2024 EX4G S SOU EXTENSION 4 GRANTED Loading...
Sep 3, 2024 EXT4 S SOU EXTENSION 4 FILED Loading...
Sep 3, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 1, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 29, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Feb 29, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Feb 29, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 23, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 21, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Aug 21, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Aug 21, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 2, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 28, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Feb 28, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Feb 28, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 13, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jul 19, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jul 19, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 29, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 15, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 15, 2022 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jun 15, 2022 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jun 15, 2022 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Jun 15, 2022 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Apr 11, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 11, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 11, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 4, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 17, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 17, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for human use for the treatment of Fabry disease and symptoms and sequelae of Fabry disease, and for the treatment of glycolipid storage disorders

Classification

International Classes
005